Comparison of Residual Cancer Burden, American Joint Committee on Cancer staging and Pathologic Complete Response in Breast Cancer after Neoadjuvant Chemotherapy: Results from the I-SPY 1 TRIAL (CALGB 150007/150012; ACRIN 6657)

PURPOSE: Several pathologic staging systems characterize residual tumor in patients undergoing neoadjuvant chemotherapy for breast cancer. Pathologic complete response (pCR) is now accepted by the Food and Drug Administration as an endpoint for granting accelerated drug approval. Two other systems o...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Breast Cancer Res Treat
Main Authors: Campbell, Jeffrey I., Yau, Christina, Krass, Polina, Moore, Dan, Carey, Lisa A., Au, Alfred, Chhieng, David, Giri, Dilip, Livasy, Chad, Mies, Carolyn, Rabban, Joseph, Sarode, Venetia R., Singh, Baljit, Esserman, Laura, Chen, Yunn-Yi
Formato: Artigo
Idioma:Inglês
Publicado em: 2017
Assuntos:
Article
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC5653207/
https://ncbi.nlm.nih.gov/pubmed/28577078
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s10549-017-4303-8
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados